Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Feb 15;60(4):611-615.
doi: 10.2169/internalmedicine.4241-19. Epub 2020 Sep 30.

Alectinib-induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma

Joe Okumoto  1 , Shinjiro Sakamoto  1 , Takeshi Masuda  1 , Kakuhiro Yamaguchi  1 , Yasushi Horimasu  1 , Shintaro Miyamoto  1 , Taku Nakashima  1 , Hiroshi Iwamoto  1 , Noriyasu Fukushima  2 , Kazunori Fujitaka  1 , Hironobu Hamada  1 , Noboru Hattori  1
Affiliations
Case Reports

Alectinib-induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma

Joe Okumoto et al. Intern Med. .

Abstract

Drug-induced immune hemolytic anemia (DIIHA) is a rare condition with an increasing incidence associated with the frequent use of certain drugs. An 85-year-old woman with lung adenocarcinoma prescribed alectinib complained of dyspnea on exertion at our hospital. Based on her laboratory tests results on admission, we focused on the clinical course of anemia and hemolysis progression after alectinib administration. The patient's anemia and hemolysis gradually improved after discontinuation of alectinib, leading to a diagnosis of alectinib-induced IHA, presented here as the first case encountered in a patient with lung adenocarcinoma. Furthermore, we discuss the importance of correlating clinical laboratory findings in DIIHA.

Keywords: alectinib; anaplastic lymphoma kinase; coombs-negative autoimmune hemolytic anemia; drug-induced immune hemolytic anemia; lung cancer.

PubMed Disclaimer

Conflict of interest statement

The authors state that they have no Conflict of Interest (COI).

Figures

Figure 1.
Figure 1.
Spherocytes (arrow) were observed in peripheral blood smear on admission.
Figure 2.
Figure 2.
Chest computed tomography (CT) on admission. (A) Chest CT from six months earlier. (B) Chest CT six months later showing no marked change in the primary tumor in left S10 compared with (A). (C) Abdominal CT of spleen taken two years earlier. (D) Abdominal CT showing spleen enlargement compared with (C). Dimensions, 78×33×70 mm→87×41×80 mm.
Figure 3.
Figure 3.
Changes in blood levels of hemoglobin, LDH, and T-Bil after the administration of alectinib. The hemoglobin level decreased, whereas the LDH and T-Bil levels gradually increased after alectinib administration. LDH: lactate dehydrogenase, T-Bil: total bilirubin
Figure 4.
Figure 4.
Changes in blood levels of hemoglobin, LDH, and T-Bil after the discontinuation of alectinib. The patient required blood transfusion only once on admission day 8 for dyspnea on exertion. The hemoglobin level then increased, while the LDH and T-Bil levels decreased gradually after alectinib discontinuation. LDH: lactate dehydrogenase, T-Bil: total bilirubin
See this image and copyright information in PMC

References

    1. Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev 24: 143-150, 2010. - PubMed
    1. Chapman AM, Sun KY, Ruestow P, Cowan DM, Madl AK. Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers. Lung Cancer 102: 122-134, 2016. - PubMed
    1. Thai AA, Solomon BJ. Treatment of ALK-positive nonsmall cell lung cancer: recent advances. Curr Opin Oncol 30: 84-91, 2018. - PubMed
    1. Open-label randomized PhaseIII Study of the Efficacy and Safety of CH5424802(AF802) in ALK-Positive Advanced or Recurrent Non-Small Cell Lung Cancer with Crizotinib control [Internet]. [cited 2019 Nov 19]. Available from: http://image.packageinsert.jp/pdf.php?mode=1&yjcode=4291032M1029
    1. Dhaliwal G, Cornett PA, Tierney LM Jr. Hemolytic anemia. Am Fam Physician 69: 2599-2606, 2004. - PubMed

Publication types